Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation Read more about Mirati Therapeutics' Adagrasib Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Patients with Advanced Non-Small Cell Lung Cancer Harboring the KRAS G12C Mutation
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology Read more about argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer Read more about Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer
Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients Read more about Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP) Read more about Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer Read more about Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials Read more about Regeneron Resumes Enrollment of FL and DLBCL Patients in Odronextamab Trials
Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation Read more about Amgen's Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation
Novocure announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the AACR Annual Meeting 2021 Read more about Novocure announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the AACR Annual Meeting 2021
Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates Read more about Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates